Pharmaceutical Stocks
Pharmaceutical filings and news · newest 5:25 PM ET · How scores work
Fri, Oct 97 events
8SBFMSunshine Biopharma Inc.Sunshine Biopharma Closes $6M Unit Offering — 43.6M Warrant Shares Loom Over 4.3M Outstanding8SBFMSunshine Biopharma Inc.Sunshine Biopharma Finalizes $6M Unit Offering at $0.55 — 43.6M Warrant Shares Loom8SXTCChina SXT Pharmaceuticals, Inc.China SXT Closes $12M Offering With Zero-Price Warrants and $12M Over-Allotment Option7PRGOPERRIGO Co plcCVC Capital Reportedly Eyeing Perrigo Takeover to Combine with Cooper Consumer Health7TEVATeva Pharmaceutical Industries LtdTeva Wins FDA Approval for Monthly Schizophrenia Injection7SBFMSunshine Biopharma Inc.Sunshine Biopharma Closes $6M Offering at $0.55, Down from $0.6876 Announced9SXTCChina SXT Pharmaceuticals, Inc.China SXT Finalizes $12M Offering With Zero-Price Warrants That Could Add 72M Shares
Thu, Oct 814 events
7TLRYTilray Brands, Inc.Tilray Q1 Loss Widens; Credit Facility Access Restricted by New Covenant Amendment8IMCCIM Cannabis Corp.IM Cannabis Registers 2.8M Shares for Resale — 170% Dilution Overhang, CEO Among Sellers7RDYDr. Reddy's Laboratories LtdAnother Form 483 for Dr. Reddy's: Two Observations at Pydibhimavaram7BFRIBiofrontera Inc.Biofrontera Seeks FDA Nod to Expand Ameluz Use to Full-Body Actinic Keratoses9PCRXPacira BioSciences, Inc.Viatris to Acquire Pacira BioSciences for $36.50/Share in $1.65B All-Cash Deal8SXTCChina SXT Pharmaceuticals, Inc.China SXT Launches $12M Registered Direct Offering, Diluting Existing Holders9VTRSViatris Inc.Viatris Launches $1.65B Tender Offer for Pacira at $36.50/Share; $62M Break Fee Disclosed9VTRSViatris IncViatris to Acquire Pacira BioSciences for $1.65B in Cash, Adding Non-Opioid Pain Franchise7SBFMSunshine Biopharma Inc.Sunshine Biopharma Prices $6M Public Offering at Steep Discount7QNTMQuantum Biopharma Ltd.Quantum BioPharma's Market Manipulation Lawsuit Consolidated; Grant & Eisenhofer Named Lead Counsel9PCRXPacira BioSciences, Inc.Viatris to Acquire Pacira BioSciences in Non-Opioid Pain Push7TLRYTilray Brands, Inc.Tilray Posts Record Q1 Revenue of $257M, Reaffirms FY27 EBITDA Guidance7TLRYTilray Brands, Inc.Tilray Q1 Revenue Jumps 23% to $257.1M, Reaffirms FY27 EBITDA Guidance8BMYBRISTOL MYERS SQUIBB COZenbexus Combo Cuts Multiple Myeloma Progression Risk by 51% in Phase 3
Wed, Oct 75 events
8RGCRegencell Bioscience Holdings LtdRegencell FY2026: Net Loss Triples to $11.7M; Auditor Flags Material Weaknesses8MDCXMedicus Pharma Ltd.Medicus Pharma Moves to Regain Nasdaq Compliance with 50-to-1 Reverse Split8PFEPfizer IncFDA Approves Pfizer's TUKYSA as Front-Line Maintenance for HER2+ Metastatic Breast Cancer7ABBVAbbVie Inc.FDA Grants Two Breakthrough Therapy Designations to AbbVie's Temab-A8RDHLRedHill Biopharma Ltd.RedHill Biopharma Gets 180-Day Nasdaq Extension to Regain $1.00 Bid Price
Tue, Oct 68 events
8ACBAurora Cannabis Inc.Aurora Urges Shareholders to Take No Action on Curaleaf's Revised US$5.00 Hostile Bid7ALVOAlvotechAlvotech Taps LOTTE Biologics for US Manufacturing to Boost Global Supply8ACBAurora Cannabis Inc.Curaleaf Raises Hostile Bid to US$5.00; Aurora Urges Shareholders to Take No Action7SCYXSCYNEXIS, Inc.SCY-770 Phase 1 Shows Favorable Safety, Phase 2 in ADPKD Set for Q47INDVIndivior Pharmaceuticals, Inc.Indivior Faces Stockholder Suits Over Merger Proxy, Bolsters Valuation Disclosures7KMDAKamada Ltd.Kamada Doubles Israeli Biosimilar Portfolio, Sets $20M-$25M Revenue Target by 20307KMDAKamada Ltd.Kamada Launches Two New Biosimilars in Israel, Targets $25M Annual Revenue by 20307QNTMQuantum Biopharma Ltd.Quantum BioPharma Taps Thermo Fisher's PPD to Run Phase 2 Lucid-MS Trial
Mon, Oct 56 events
8ACBAurora Cannabis Inc.Curaleaf Raises Hostile Bid to US$5.00/Share; Aurora Extends Deadline to Dec 47ABBVAbbVie Inc.AbbVie Guides Q3 EPS Below Consensus on $216M IPR&D Charge8ABBVAbbVie Inc.AbbVie-Genmab Combo Cuts DLBCL Progression Risk by 51% in Phase 38LLYELI LILLY & CoFDA Approves Jaypirca as First-Line CLL/SLL Therapy, Expanding Lilly's Oncology Reach8AZNAstraZeneca PLCAstraZeneca Completes $2B Equity Investment in Summit Therapeutics7HROWHarrow, Inc.Harrow Closes TYRVAYA Acquisition with Revised Terms: Japan Rights Retained by Viatris, $30M Fixed Cash Consideration
Pharmaceutical companies on Wiseek (93)
Each company page tracks that company's SEC filings, news and market data.
ABBVACBAKANALKSALVOAMGNAMPHAMRNAMRXANIPAQSTASRTAYTUAZNBFRIBGMBHCBIIBBIOABMYCABRCGCCOLLCPIXCRDLCRONCTORDERMEBSELANELTPEOLSESPRETONEVOGELSGILDGRFSGSKHCMHLNHROWIMCCINCRINDVINISIRWDIXHLJNJKALAKMDALFCRLLYLNTHMDCXMIRAMRKNBIXNVSOGIOGNORGOPAHCPBHPCRXPFEPRFXPRGOPTPIQNTMRDHLRDYRGCSBFMSCLXSCYXSHPHSIGASNOASNYSUPNSXTCTAKTEVATKNOTLPHTLRYTXMDUPCVTRSZSTKZTSZYBT
How Wiseek picks and scores these
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a pharmaceutical company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
See the full Healthcare sector feed.